Posts tagged Biomarker Qualification.
Blogs
less than a minute
On December 11, 2018, the Food and Drug Administrative (“FDA”) issued a draft guidance for comment entitled, “Biomarker Qualification: Evidentiary Framework” (the “Guidance”). The Guidance provides insight regarding standards for biomarker qualification under the 21st Century Cures Act (“Cures Act”).
FDA defines the term “biomarker” as a “characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions.” There are various ...
Back to Health Law Advisor Blog
Recent Updates
- Federal Regulatory Views on Cybersecurity and AI Amidst a Growing Threat Landscape
- Remote Monitoring Services Under the 2027 PFS Proposed Rule: Epstein Becker Green Submits Comments to CMS
- New DOL Guidance Reiterates Key Priorities for MHPAEA Enforcement
- The Largest Sunshine Act Penalty in History - Pharmaceutical Company Settles False Claims Act, Anti-Kickback Statute and Sunshine Act Allegations
- FTC Reverses Course on Health App Privacy